PUBLIC COMPANY
save$EWTXEdgewise Therapeutics, Inc.
$EWTX45.93+0.24%Boulder, CO, USupdated 3d ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase1A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment
- phase2Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)
- phase2Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
- phase1A Study to Evaluate EDG-7500 in People With Renal Impairment
- phase1A Study to Evaluate EDG-7500 in Caucasian and Japanese Adults
- phase2A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)
- phase2A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)
- phase2Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy
🐶 Hiring Signal
News
- STAT+: Servier’s $1.55 billion muscular dystrophy drug fails first major testServier reports a surprise setback for a drug being tested for a form of muscular dystrophy that lacks treatment.stat · 13d ago
- Servier buys into muscular dystrophy with potentially $2.7B dealThe French drugmaker has agreed to acquire an experimental tablet from Edgewise Therapeutics that some bullish analysts say could eventually hit peak sales of over $2 billion.biopharma_dive · 5mo ago
Data sources
last refreshed 13m ago
Found something off?
comments(0)
5-min edit window · permanent after that